New blood biomarkers reveal how common muscular dystrophy treatment may impair overall growth
A study published in Scientific Reports identifies blood biomarkers that explain how the corticosteroid prednisone negatively impacts bone health and growth in children with Duchenne muscular dystrophy. The research suggests that an alternative drug, vamorolone, does not cause these same growth-impairing side effects.
Why it matters
This finding could lead to safer long-term treatment protocols for children suffering from muscular dystrophy.
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Eric Hoffman, Associate Dean for Research and Research Development and Professor, Binghamton University School of Pharmacy and Pharmaceutical Sciences. Hoffman was the senior author of the study. Credit: Binghamton University, State University of New York In a study published in Scientific Reports , an international, multidisciplinary research team that included Binghamton University researchers identified a set of blood proteins that may explain why the corticosteroid prednisone, although beneficial in treating Duchenne muscular dystrophy (DMD), can interfere with childhood growth and bone health.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in